Join
Live feed
·
PRReleasevia Quantisnow
Adverum Biotechnologies Inc. logo

Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

ByQuantisnow·Wall Street's wire, on your screen.
ADVM· Adverum Biotechnologies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADVM (Adverum Biotechnologies Inc.) and more on Quantisnow.